In a preliminary study we have administered medroxyprogesterone acetate to 20 patients with advanced metastatic prostatic cancer, who no longer responded to previous therapy. The dose used was 1,000 mg intramuscularly three times a week for 5 weeks, followed by 1,000 mg weekly until progression. All patients had undergone orchidectomy or had been treated with estrogens. 15 patients also had received estramustine, and another 3 patients,chemotherapy. A partial response occurred in 4 patients for periods of up to 18 months, and stable disease was seen in 2 patients. 7 more patients reported subjective response lasting less than 2 months. The disease progressed in the remaining 7 patients. Adverse reactions were tolerable. Our results are promising and indicate that medroxyprogesterone in high doses may have an effect in therapy-resistant cases of prostatic carcinoma.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.